More money, more gabapentin

Pharmaceutical companies' payments to doctors may be influencing them to prescribe more expensive, brand-name versions of the pain drug gabapentin, a team of researchers report in the July 8 issue of JAMA Internal Medicine, and the increasing use of the drug suggests it may be being abused.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news